Wortmannin

Catalog No.S2758 Synonyms: KY 12420

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 98 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 M4TwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[yMlUh|ryP M{TVU|EuPCCm MlLzSG1UVw>? MX;lcohidmOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKHS{ZXH0cYVvfCC5aYToJJRidW:6aX\lci=> NXK1fVVvOjV2OUCzPFM>
H1703 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV6yMlUh|ryP NWi5[FJMOS12IHS= MVHEUXNQ NX;XV21t\W6qYX7j[ZMh[2WubDDndo94fGhiaX7obYJqfGmxbjD0doVifG2nboSge4l1cCC2YX3vfIln\W5? MUOyOVQ6ODN6Mx?=
HUVECs MmrQR5l1d3SxeHnjbZR6KEG|c3H5 NFW5fVYyODBibl2= NWLwc4l2OjRiaB?= MmLoZZR1\W63YYTld{B1cGViYXLyc4difGm4ZTDl[oZm[3S|IH;mJINidHmlb4PpckBwdiCYUlmtbY5lfWOnZDDjfZRwfG:6aXPpeJk> NFrufXkzPTR3MEG4Oi=>
APRE-19 M4PiSWFxd3C2b4Ppd{BCe3OjeR?= MlftOUDPxE1? NVvRZohjOjRiaB?= NYTmUYxu[WKxbHnzbIV{KE[OWj3t[YRq[XSnZDDwdo8ue3W{dnn2ZYww[W62aT3hdI9xfG:|aYOgZYN1cX[rdIm= MUmyOVMzQTZzNx?=
MDA-MB-231 NGLyenBCeG:ydH;zbZMhSXO|YYm= M1n5ZlHDqM7:TdMg NHLSO2U1QCCq MoPKSG1UVw>? MULk[YNz\WG|ZYOgeIhmKGOnbHygd5Vzfmm4YXygeJJm[XSnZDD3bZRpKDJ3IN88UUBw\iCIMTDvdkBHOiEEoB?= MkC4NlU{ODB7M{K=
MCF7 MmHDSpVv[3Srb36gRZN{[Xl? MkTnNVAxKG6P NXnQSZR2OjRiaB?= MoLC[YxqdWmwYYTld{BGOi2rbnT1Z4VlKEGURT3MeYMh[WO2aY\peJk> MU[yOVE4OjV3Nx?=
HT-29  NXztbldNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13iPVEvPcLiwsXN MknQPVYhcA>? MX\k[YNz\WG|ZYOgZ4VtdCCpcn;3eIghf2irY3igZ4FvKGKnIHnubIljcXSnZDDifUBMYU6D MljUNlUxOTJzMkO=
MO59K  NVn1T4Z2S3m2b4TvfIlkcXS7IFHzd4F6 MoW5OeKh|ryP Mn60O{Bl NUTUNmxsTE2VTx?= M4PVNYVvcGGwY3XzJJRp\SCleYTveI95cWOrdImgc4Yh\XSxcH;zbYRmKG:{IHPpd5Bt[XSrbh?= MX[yOFk2OzV4MR?=
MO59J NYeweY11S3m2b4TvfIlkcXS7IFHzd4F6 NGm0dVM2yqEQvF2= Mne2O{Bl NGTVOoFFVVOR MXLlcohidmOnczD0bIUh[3m2b4TvfIlkcXS7IH;mJIV1d3Cxc3nk[UBweiClaYPwcIF1cW5? M1vvclI1QTV|NU[x
MO59K  M4W2WGFxd3C2b4Ppd{BCe3OjeR?= NHP5UYwyOCEQvF2= MWeyOEBp NWD6elNHTE2VTx?= NYS5bVZvcW6lcnXhd4V{KHSqZTDEV2IhdGW4ZXygbY5lfWOnZDDifUBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw MV6yOFk2OzV4MR?=
MO59J MYjBdI9xfG:|aYOgRZN{[Xl? Mne3NVAh|ryP NWPUW4J{OjRiaB?= M3jnbGROW09? MWLpcoNz\WG|ZYOgeIhmKESVQjDs[ZZmdCCrbnT1Z4VlKGK7IHX0c5Bwe2mmZTDvdkBkcXOybHH0bY4> MknINlQ6PTN3NkG=
HepG2 M4LC[2Z2dmO2aX;uJGF{e2G7 M4XreVExOCCwTR?= M2T2U|AvPSCq NX\ocZN[TE2VTx?= M2XNbIJtd2OtczDNRU1qdmS3Y3XkJGFsfCCyaH;zdIhwenmuYYTpc44> NIXSPW0zPDh4M{O1NC=>
A549  MoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTwVpo{KML3TdMg M3mwblIhcA>? MmHDd5VxeHKnc4Pld{Bx\W2ndILlfIVlNWmwZIXj[YQhSWu2IHHu[EBIW0t|zsKgZYN1cX[jdHnvckwhWy2yaHHz[UBienKnc4SsJINmdGxiYYDvdJRwe2m|IHHu[EBk[XOyYYPlMVMh[WO2aY\heIlwdg>? MkLxNlQ5PDd6NkO=
A549  MkXLSpVv[3Srb36gRZN{[Xl? NHnzcIoyOMLizsztxsA> NF3EV5UyPiCq NGXDcXFFVVOR Mkf5cY9lfWyjdHXzJJRp\SCLQW[gdoVxdGmlYYTpc44h[W6mIHPheZNmeyC{ZYTlcpRqd25ib3[gUnAhcW5idHjlJI52[2yndYOu M{nWSFI1QDB{MUGx
SK-N-LO MXzGeY5kfGmxbjDBd5NigQ>? NVXEUpExOTByIH7N M4HG[lAvPSCq MUHk[YNz\WG|ZYOgeIhmKHO2aX31cIFvfCCnZn\lZ5R{KG:oIH3vdpBpcW6nIH;uJGFsfCCyaH;zdIhwenmuYYTpc44> NUfzOmNYOjR4NUS2NFY>
HL-60 MlPOSpVv[3Srb36gRZN{[Xl? M2\4NlAvOcLizszN NFrjepI4OiCq M1TwV4Jtd2OtczDkZZNifGmwaXKtbY5lfWOnZDDj[YxtKGSrZn\ldoVvfGmjdHnvci=> MmSzNlQ3ODd{N{O=
HepG2  MmXpSpVv[3Srb36gRZN{[Xl? MXyyNFAhdk1? M{\VTVAvPSCq MlvDZZR1\W63YYTld{BHd3iRIIDoc5NxcG:{eXzheIlwdg>? MmfENlQ2OzVzOUK=
H520 MnLBSpVv[3Srb36gRZN{[Xl? MYWxNOKh|ryP MV[xJIg> NULEUW1[TE2VTx?= M4fFRYRm[3KnYYPld{Bk\WyudXzhdkBxcG:|cHjvMWFMXCCycn;0[YlvKGyndnXsdy=> MXSyOFQ1Pzl|NR?=
H1975 M1jw[mZ2dmO2aX;uJGF{e2G7 MV[xNOKh|ryP NITIXooyKGh? NFfOTXJFVVOR MUTk[YNz\WG|ZYOgZ4VtdHWuYYKgdIhwe3Cqbz3BT3QheHKxdHXpckBt\X[nbIO= M3HSO|I1PDR5OUO1
MG-63 MnvPRZBweHSxc3nzJGF{e2G7 NYL3blBkOTBiwsXN MXuxNkBp NXq2RYdL\W6qYX7j[ZMhTFBvaX7keYNm\CCjcH;weI9{cXN? M2fBe|I1OzV6M{Cx
5637 NFLNRXhCeG:ydH;zbZMhSXO|YYm= NXz1ZVNMOTEEoN88US=> NVXMN4o2PDBibXnu NYPTUVY{emW4ZYLz[ZMheDJzV1HGNUBmgHC{ZYPzbY9vNCCFRFug[ZhxemW|c3nvckwh[W6mIHPlcIwhcW6qaXLpeIlwdiCrbnT1Z4VlKGK7IH\1Z49q\GGw MWiyOFM{Ozh4OB?=
HEK-293 Mn\LSpVv[3Srb36gRZN{[Xl? NXjpOHJUOTVybl2= MXexOkBp MXXEUXNQ NXTT[FdM\GWlcnXhd4V{KEOUVDDhZ5Rqfmm2eR?= MlTBNlQ{OjR|Nk[=
SW480  MnXUSpVv[3Srb36gRZN{[Xl? MUCxOVBvVQ>? M1jjUlIxKGh? Mm\WSG1UVw>? MXPy[YR2[2W|IHPlcIx2dGG{IHHjZ5VufWyjdHnvckBw\iEQsj3jZZRmdmmw MUSyOFMzPDN4Nh?=
HepG2 NI[1[lhHfW6ldHnvckBCe3OjeR?= M1fk[|ExOCCwTR?= Mnv2NlQhcA>? MVPheJRmdnWjdHXzJJRp\SClb3zvcolmeyCxZjD0bIUhfHWvb4KgZ4VtdHNid3n0bEB2eHKnZ4XsZZRqd25ib3[gRYt1OQ>? MWWyOFI6PzVzMB?=
HCT 116  MonsSpVv[3Srb36gRZN{[Xl? NYDXRY1SOTByIH7N NEPQVGEzPCCq NVzrSXdp[XS2ZX71ZZRmeyC2aHWgZ49td26rZYOgc4YhfGinIIT1cY9zKGOnbHzzJJdqfGhidYDy[Yd2dGG2aX;uJI9nKEGtdEG= NWD2R5U6OjR{OUe1NVA>
BEL/FU NHrPbGxHfW6ldHnvckBCe3OjeR?= MWqxJI1O MWiyOEBp MmnM[IVkemWjc3XzJJBzd3SnaX6gcIV3\Wy|IH;mJJRp\SCSSUPLM2FsfCCyYYToe4F6 NHLFc|YzPDJ|MkC5PS=>
Huh7  M4T3R2Z2dmO2aX;uJGF{e2G7 NUjUdG9IO8LizszN NVjMdpp4OSCq MnrBdoVlfWOnczD0bIUhfmm{dYOg[Y51enliaX70c{B1cGViY3XscJM> MoriNlQyQDRzOU[=
A-375 M4HjTWFxd3C2b4Ppd{BCe3OjeR?= MVW0M|gh|ryP MYGyOEBp NUnZeJFm\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> M3SxZlI1OTF|MUez
A-375-TS  MkTRRZBweHSxc3nzJGF{e2G7 M1iw[|QwQCEQvF2= NXm1OJBxOjRiaB?= NXO5WmlE\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> NYrkT45UOjRzMUOxO|M>
Mel-HO M{nUTmFxd3C2b4Ppd{BCe3OjeR?= MlrIOE85KM7:TR?= M3K1O|I1KGh? NUK1ZXJv\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> M1jnbVI1OTF|MUez
Mel-HO-TS NHnkPJhCeG:ydH;zbZMhSXO|YYm= MUi0M|gh|ryP M3XCU|I1KGh? NVfh[XYz\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> NWP4RXljOjRzMUOxO|M>
MeWo M4[4[2Fxd3C2b4Ppd{BCe3OjeR?= M17aVVQwQCEQvF2= MmHBNlQhcA>? NXnySmpM\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> NX\3[ZJYOjRzMUOxO|M>
Mel-2a MVXBdI9xfG:|aYOgRZN{[Xl? M1rQ[lQwQCEQvF2= NHfYbIYzPCCq NG[0U4VmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg MXuyOFEyOzF5Mx?=
MDA-MB-231 M4rFWWZ2dmO2aX;uJGF{e2G7 M3ezSVDjiJN2MECgcm0> MXS0JIg> NFr2[5l{fXCycnXzd4V{KEGtdDDwbI9{eGixconsZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWmyNlkxPjJ3OR?=
MDA-MB-231 MmHJSpVv[3Srb36gRZN{[Xl? MUC0NFAhdk1? MVe0JIg> MnT5[IVkemWjc3XzJG1OWC17IHHu[EBKVC16IIDyc5RmcW5iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1fuSlIzQTB4MkW5
Jurkat M4\rTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4flV|AvOjVvMT6yOUDPxE1? M3jzRVI1NzR6IHi= MlzGSG1UVw>? MorNbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvIHTldIVv\GWwdDDtZY5v\XJ? NXvMcYQ4OTl5NUexPFU>
Namalwa MnfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonKNE4zPS1zLkK1JO69VQ>? MoTzNlQwPDhiaB?= M2LiZmROW09? MlrQbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvIHTldIVv\GWwdDDtZY5v\XJ? M4K4XlE6PzV5MUi1
Jurkat NUfOTZRZSXCxcITvd4l{KEG|c3H5 MUiwMlI2NTFwMkWg{txO MV[yOE81QCCq MVLEUXNQ MnrZbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy NXLPcotqOTl5NUexPFU>
Namalwa M2S0WGFxd3C2b4Ppd{BCe3OjeR?= NE[3VIsxNjJ3LUGuNlUh|ryP M{G3SVI1NzR6IHi= Ml34SG1UVw>? MlT2bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy MYGxPVc2PzF6NR?=
K562 M1m0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4i3V|I1KGh? M3K2NWlEPTB;MkZCtVAvOTRibl2= M2PXUFE6PjZ{M{[x
SW1990 M1fHTmZ2dmO2aX;uJGF{e2G7 NUfKTVZsOC5yMT2xJO69VQ>? MVKxJIg> MVvpcohq[mm2czDIRU1qdmS3Y3XkJGFsfCCyaH;zdIhwenmuYYTpc44> NY\SS2NmOTl2NkmwNlA>
RT112  NG\FWGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTxb4QyOMLizszN MUCyOEBp MnH1SG1UVw>? Mn\l[IVkemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJGczN01iY3XscJM> NXjpdGY3OTh5OEe4N|I>
MHG-U1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVOxNOKh|ryP M13oT|I1KGh? MY\EUXNQ NX3VNHdy\GWlcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKEd{L12gZ4VtdHN? Mme0NVg4QDd6M{K=
SMMC-7721 NWO5OlRzSXCxcITvd4l{KEG|c3H5 MWiyNFDDqG6P MVeyOEBp MkDlbY5kemWjc3XzJGNJYC2rbnT1Z4VlKGGyb4D0c5Nqew>? MXyxO|U2PzF7MR?=
SMMC-7721 NEX5OotHfW6ldHnvckBCe3OjeR?= NF3FcmozODEEoH7N NEjhc5UzPCCq NXvITIpVfXBvcnXneYxifGW|IN8yNUw1T1RzIHX4dJJme3Orb36= Mm\4NVc2PTdzOUG=
HeLa MXvGeY5kfGmxbjDBd5NigQ>? NXjWbWRROTBywrDuUeKh MmrXNUBp NXPVR3h2[Wy2ZYLzJJRp\SCvb4LwbI9td2e7IH;mJJRp\SC2cnHud4ZmenKrbjDy[YN6[2yrbnegZ49ueGG{dH3lcpQ> NVm3PINIOTZ6OUC5NVU>
MRC5VI NVrOcJZvTnWwY4Tpc44hSXO|YYm= NX7BVGJIOTJwNTDtUS=> M4DVbVAvPSCq M3zifGROW09? M1rJ[4Fjd2yrc3jld{B1cGViU3XyOFc{N1SqckOwPOKheGixc4Doc5J6dGG2aX;uJI9nKEGtdGDLRuKh MV2xOlIzPzN7NB?=
AT5BIVA NHTIWnhHfW6ldHnvckBCe3OjeR?= NGjXfnoyOi53IH3N MXWwMlUhcA>? M4XSc2ROW09? M4rsW4Fjd2yrc3jld{B1cGViU3XyOFc{N1SqckOwPOKheGixc4Doc5J6dGG2aX;uJI9nKEGtdGDLRuKh NHH1PY4yPjJ{N{O5OC=>
M059J MVLGeY5kfGmxbjDBd5NigQ>? MlnFNVIvPSCvTR?= MlGyNE42KGh? NFrJNm1FVVOR M1WwVoFjd2yrc3jld{B1cGViU3XyOFc{N1SqckOwPOKheGixc4Doc5J6dGG2aX;uJI9nKEGtdGDLRuKh Ml6wNVYzOjd|OUS=
HeLa M1fXZWZ2dmO2aX;uJGF{e2G7 MVSxNk42KG2P M33HNFAvPSCq M1mxTmROW09? NFLQbmVi[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? NXrvUYRYOTZ{MkezPVQ>
N2a MX7BdI9xfG:|aYOgRZN{[Xl? NEPKPIwxNjFvMUCg{txO MlTXNkBp MnzjbY5lfWOnczDk[YNz\WG|ZXSgZ4VtdCC4aXHibYxqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? MUWxOVg1Ojd4Nx?=
Jurkat  MWLLbY5ie2ViQYPzZZk> NVfNOI9pUUN3MDDv[kAzPCCwTR?= MWCxOVY3PDVzOR?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT / p-GSK3β / GSK3β / Bcl-xl / Bax / Caspase-3 / Cleaved caspase-3; 

PubMed: 25344912     


Four esophageal cancer cell lines were treated with different concentrations of wortmannin for 48 h, and cell lysates were collected for Western blot analysis of p-AKT, AKT, p-GSK3β, GSK3β, Bcl-xL, Bax, caspase-3, and cleaved caspase-3.

25344912
Immunofluorescence
DNMT1; 

PubMed: 24001151     


PC3 cells were treated with DMSO or wortmannin (1 μM) for 24 hours. DNMT1 and DNMT3B cellular localization was visualized by immunofluorescent staining. After 24h of treatment, cells were fixed in methanol, incubated with the indicated antibodies, stained with Alexa Fluor 594-tagged secondary antibodies and counterstained with DAPI. Slides were then mounted and examined under a fluorescence microscope. The bright field images of PC3 cells treated with DMSO or wortmannin (1 μM) for 24 hours are shown (right panel).

24001151
Growth inhibition assay
Cell viability; 

PubMed: 25344912     


MTT assay was used to determine the effects of different concentrations of wortmannin on viability of esophageal cancer cells lines KYSE150, HKESC-1, KYSE270, and T.Tn. Bars, SD; * P < 0.05; **, P < 0.01; ***, P < 0.001 compared with DMSO-treated cells.

25344912
In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol

Animal Research:[11]
- Collapse
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Formulation: Dissolved at 0.4 mg/mL in DMSO, and diluted with 0.9% NaCl before use
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage powder
in solvent
Synonyms KY 12420

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Wortmannin | Wortmannin supplier | purchase Wortmannin | Wortmannin cost | Wortmannin manufacturer | order Wortmannin | Wortmannin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID